Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
Mauro FR, Scalzulli PR, Scarfò L, Minoia C, Murru R, Sportoletti P, Frigeri F, Albano F, Di Renzo N, Sanna A, Laurenti L, Massaia M, Cassin R, Coscia M, Patti C, Pennese E, Tafuri A, Chiarenza A, Galieni P, Perbellini O, Selleri C, Califano C, Ferrara F, Cuneo A, Murineddu M, Palumbo G, Scortechini I, Tedeschi A, Trentin L, Varettoni M, Pane F, Liberati AM, Merli F, Morello L, Musuraca G, Tani M, Ibatici A, Regazzoni G, Di Candia M, Palma M, Arienti D, Molica S. Mauro FR, et al. Among authors: perbellini o. Cancers (Basel). 2024 Mar 20;16(6):1228. doi: 10.3390/cancers16061228. Cancers (Basel). 2024. PMID: 38539561 Free PMC article.
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia.
Moia R, Dondolin R, De Propris MS, Talotta D, Mouhssine S, Perutelli F, Reda G, Mattiello V, Rigolin GM, Motta M, Olivieri J, Fanin R, Perbellini O, Ferrarini I, Mauro FR, Del Giudice I, Laurenti L, Tomasso A, Gentile M, Frustaci AM, Tedeschi A, Gozzetti A, Stelitano C, Visco C, Moreno C, Forconi F, Marasca R, Coscia M, Rossi D, Foà R, Gaidano G. Moia R, et al. Among authors: perbellini o. Hematol Oncol. 2023 Aug;41(3):567-570. doi: 10.1002/hon.3080. Epub 2022 Oct 10. Hematol Oncol. 2023. PMID: 36190298 No abstract available.
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi.
Merli M, Rattotti S, Spina M, Re F, Motta M, Piazza F, Orsucci L, Ferreri AJM, Perbellini O, Dodero A, Vallisa D, Pulsoni A, Santoro A, Sacchi P, Zuccaro V, Chimienti E, Russo F, Visco C, Zignego AL, Marcheselli L, Passamonti F, Luminari S, Paulli M, Bruno R, Arcaini L; Fondazione Italiana Linfomi. Merli M, et al. Among authors: perbellini o. J Clin Oncol. 2022 Dec 10;40(35):4060-4070. doi: 10.1200/JCO.22.00668. Epub 2022 Jun 17. J Clin Oncol. 2022. PMID: 35714311 Free PMC article.
Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells.
Dalla Pietà A, Cappuzzello E, Palmerini P, Ventura A, Visentin A, Astori G, Chieregato K, Mozzo V, Perbellini O, Tisi MC, Trentin L, Visco C, Ruggeri M, Sommaggio R, Rosato A. Dalla Pietà A, et al. Among authors: perbellini o. J Immunother Cancer. 2021 Jul;9(7):e002475. doi: 10.1136/jitc-2021-002475. J Immunother Cancer. 2021. PMID: 34272306 Free PMC article.
Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases.
Mimiola E, Bomben R, De Matteis G, Perbellini O, Guglielmelli P, Bonifacio M, Parisi A, Gattei V, Zamò A, Mannelli F, García Montero AC, Zanotti R. Mimiola E, et al. Among authors: perbellini o. Hematol Oncol. 2019 Dec;37(5):628-633. doi: 10.1002/hon.2680. Epub 2019 Oct 21. Hematol Oncol. 2019. PMID: 31523839
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.
Diop F, Moia R, Favini C, Spaccarotella E, De Paoli L, Bruscaggin A, Spina V, Terzi-di-Bergamo L, Arruga F, Tarantelli C, Deambrogi C, Rasi S, Adhinaveni R, Patriarca A, Favini S, Sagiraju S, Jabangwe C, Kodipad AA, Peroni D, Mauro FR, Giudice ID, Forconi F, Cortelezzi A, Zaja F, Bomben R, Rossi FM, Visco C, Chiarenza A, Rigolin GM, Marasca R, Coscia M, Perbellini O, Tedeschi A, Laurenti L, Motta M, Donaldson D, Weir P, Mills K, Thornton P, Lawless S, Bertoni F, Poeta GD, Cuneo A, Follenzi A, Gattei V, Boldorini RL, Catherwood M, Deaglio S, Foà R, Gaidano G, Rossi D. Diop F, et al. Among authors: perbellini o. Haematologica. 2020 Jan 31;105(2):448-456. doi: 10.3324/haematol.2019.219550. Print 2020. Haematologica. 2020. PMID: 31371416 Free PMC article.
Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.
Tisi MC, Paolini R, Piazza F, Ravelli E, Tecchio C, Sartori R, Famengo B, D'Amore ESG, Carli G, Perbellini O, Di Bona E, Ruggeri M, Visco C. Tisi MC, et al. Among authors: perbellini o. Am J Hematol. 2018 Dec;93(12):E386-E389. doi: 10.1002/ajh.25278. Epub 2018 Oct 9. Am J Hematol. 2018. PMID: 30184246 Free article. Clinical Trial. No abstract available.
62 results